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STUDY OF RELATIONSHIP BETWEEN PLASMA 
HOMOCYSTEINE LEVELS AND GESTATIONAL 
HYPERTENSION 
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ABSTRACT: 
OBJECTIVE: 
                        To find out the relationship between plasma homocysteine levels 
and occurrence of gestational hypertension.  
METHODS: 
                        A case control study with 50 cases who were postnatal patients with 
gestational hypertension and 61 controls who were postnatal patients with 
uncomplicated obstetric histories. Of the 50 cases, 16 had gestational hypertension, 
26 had preeclampsia and 8 had Eclampsia.   Plasma homocysteine was determined 
by Chemi luminescence immunoassay method.  For statistical analysis chi square 
test and the student t test were used. Pearson co-relation coefficient was used to 
detect the correlation. 
 RESULTS:   
                          Mean Plasma homocysteine levels were found to be 
significantly higher in cases    compared to controls. Mean Plasma homocysteine 
levels in normal mothers was 10.50µmol/L, in mothers with gestational 
hypertension was 16.43µmol/L and in preeclampsia was 20.23µmol/L.  There was 
significant association between positive family history of cardiovascular disease 
and gestational hypertension (p<0.001). There was also significant association 
between plasma homocysteine and positive family history of cardiovascular 
disease (p<0.05). Significant association existed between plasma homocysteine 
levels and gestational hypertension (p<0.001).  Plasma homocysteine levels in 
preeclampsia are higher than that in gestational hypertension (p<0.001). Positive 
correlation was found between plasma homocysteine levels and Mean Arterial 
Pressure (r=0.447, p=0.000), Systolic Blood Pressure (r=0.559, p=0.000) and 
Diastolic Blood Pressure (r=0.334, p=0.000).   
CONCLUSION: 
                         A relationship exists between plasma homocysteine levels and 
gestational hypertension. Higher  levels of  plasma  homocysteine levels  are found  
in  women  with gestational  hypertension  compared  to normotensive  pregnant  
women.   
  
 
 
 
INTRODUCTION
                 Hypertensive disorders represent the most common medical 
complication of pregnancy with a reported incidence between 5 and 10 
percent. The term hypertension in pregnancy is commonly used to describe a 
wide spectrum of patients who may have only mild elevations in blood 
pressure or severe hypertension with various organ dysfunctions.
                     The three most common forms of hypertension are gestational 
hypertension, preeclampsia and chronic essential hypertension.
                       Hypertensive disorders  together  with  haemorrhage  and 
infection form  a deadly triad  that  contribute  greatly  to maternal  
morbidity and mortality. In India it accounts for 24% of all maternal deaths. 
Among the three leading causes of the maternal death, Hypertensive 
disorders top the list. It is also a major cause of preterm birth, intrauterine 
growth restriction and perinatal mortality.
                       How pregnancy incites or aggravates hypertension remains 
unsolved despite, decades of intensive research. Indeed hypertensive 
disorders remain among the most significant and intriguing unsolved 
problems in Obstetrics. The risk factors are still not well understood, so 
there is lack of sensitive tests.
                     Recent research  also reveals  that  many changes  precede  any  
increase  in BP  and  though  the symptoms  and signs  usually  become 
apparent  in the third trimester, the underlying pathophysiological  
mechanisms  appear  between    8-18  weeks of  gestation. 
                       Endothelial   damage has been implicated in the etiology of 
gestational hypertension. Homocysteine is a non protein sulphur containing 
aminoacid which is notorious for causing endothelial damage. It has been 
proved  that  homocysteine  has a definite  role  in the setting  of  coronary   
artery disease, peripheral  arterial  disease, Cerebrovascular disease,  DVT 
and Neural tube defects. 
                          The incidence of gestational hypertension is high about 15% 
to 18% in Coimbatore. The reason could be its unique climate because of the
flow of cool breeze all round the year through the Palakkad gap of Western 
Ghats. Further there are other possible factors such as concentration of 
industrial labour force due to the presence of more textile and engineering 
industries, conglomeration of different ethnic populous and the geographical 
location, which could be the other reasons. The etiology is yet to be 
unraveled. 
                         Hence studies on gestational hypertension are the need of the 
hour.   With this background this study aims at finding the relationship 
between plasma homocysteine and gestational hypertension.
Aims and Objectives
AIMS AND OBJECTIVES 
Aims: 
This study is designed to find out the relationship between plasma 
homocysteine levels and occurrence of gestational hypertension. 
Objectives: 
 To measure plasma homocysteine levels in normotensive and   
gestational hypertension patients. 
   To compare plasma homocysteine levels in both the groups. 
   To establish a relationship between plasma homocysteine and           
gestational hypertension. 
   To find out possible factors that might influence plasma    
homocysteine levels in hypertensive disorders of pregnancy. 
Review of Literature
REVIEW OF LITERATURE
GESTATIONAL HYPERTENSION
HISTORICAL PERSPECTIVE 
                     Gestational hypertension contributes to the ancient times. 
Eclampsia was identified by the pre Hippocratic Kahun papyrus from Egypt 
3000 years back. PIH was recognized by ancient Greeks. They believed that 
in pregnant women, the appearance of heaviness, drowsiness and headaches 
is not a good sign and that they have the possibility to develop some kinds of 
seizures. 
                    Galen’s commentary on Hippocrates aphorisms recommends 
that he was familiar with the aggressive features in pregnant women1, 2.
                     St.Gall, a well known practitioner in the 10 th century AD had 
a trick played on him. He was  about  to examine the Duke of Bavaria  and  
as a deception  the valuable nobleman  replaced  for  his urine  that  of a 
woman who was pregnant. After examination St. Gall made a statement that 
the Duke would give birth to a child. This event is possibly the first evidence 
of finding protein in urine of pregnant woman.              
                      Technical description on PIH actually started indirectly in 17th
century.  The term eclampsia appeared in a treatise on Gynaecology written 
by Varandaeus in 1619. It was coined by Hippocrates, meaning flash1, 35, 42.  
                       Blundell, Mauriceau and Bartonand, all these three have 
documented the signs of PIH. In the year 1840, Rayer detected protein in 
urine of three pregnant women with edema who had PIH. Old time 
practitioners of medicine though crude by today’s standard, had documented 
raised blood pressure in women with PIH by examining their stiff bounding 
pulses. 
                        In 1884, Vinay used ancient sphygmomanometer to measure 
BP. Further research was conducted in the ensuing years and now it is at the 
current scenario. 
                         If  we look at  the past,  present  and  think of future with 
reference to the relevancy of this  disease,  it is evident  that the names  have 
been ever changing  from toxaemia to  gestosis and so on, but  the disease  
continues  unabated  with  high materno-fetal loss, however   the research  
also continues 2,38 unabatedly without  any  pause.             
TERMINOLOGY & CLASSIFICATION
                      The term gestational hypertension was chosen by Dr. Jack 
Pritchard to describe any new onset uncomplicated hypertension during 
pregnancy when no evidence of the preeclampsia syndrome was apparent.
                     The working group classification of hypertensive disorders 
complicating pregnancy describes four types of hypertensive disease3:
1. Gestational Hypertension- Formerly termed pregnancy induced 
Hypertension. If preeclampsia syndrome does not develop and 
hypertension resolves by 12 weeks postpartum, it is 
redesignated as transient hypertension.
2. Preeclampsia & eclampsia syndrome
3. Preeclampsia syndrome superimposed on chronic hypertension
4. Chronic hypertension
An important feature of this classification is differentiating preeclampsia & 
eclampsia from other hypertensive disorders because former two are 
potentially more ominous.
Gestational Hypertension:
 Systolic BP>140 or diastolic BP> 90mm Hg for first time 
during pregnancy.
 No proteinuria
 BP returns to normal before 12 weeks postpartum
 Final diagnosis made only postpartum
 May have other signs & symptoms of preeclampsia. For 
example epigastric discomfort, thrombocytopenia 3,6,11.
Preeclampsia
Minimum criteria
 BP>140/90mmHg after 20 weeks gestation, proteinuria > 
300mg/24hours or > 1+ dipstick.
Increased certainty of preeclampsia:
 BP > 160/110mmHg 
 Proteinuria 2.0g/24hours or > 2+ dipstick
 Serum creatinine >1.2mg/dl unless known to be previously 
elevated
 Platelets <1,00,000/µl
 Microangiopathic hemolysis – increased LDH
 Elevated serum transaminase levels-ALT\AST
 Persistent headache or other cerebral or visual disturbance.
 Persistent epigastric pain
 Preeclampsia is best described as a pregnancy specific 
syndrome that can affect virtually every organ system.
 Some women may have a typical preeclampsia with all aspects 
of syndrome but without hypertension or proteinuria or 
both11,12,14.
 Indicators of severity of Gestational Hypertensive disorders.
Abnormality Non severe Severe
Diastolic BP <110mm Hg >110mm Hg
Systolic BP <160mm Hg >160mm Hg
Proteinuria <2+ >3+
Headache Absent Present
Visual disturbances Absent Present
Upper Abdominal Pain Absent Present
Oliguria Absent Present
Convulsion Absent Present
Serum creatinine Normal Elevated
Thrombocytopenia Absent Present
Serum Transaminase 
elevation
Minimal Marked
Fetal growth restriction Absent Obvious
Pulmonary Edema Absent Present
          
                  The differentiation between non severe & severe gestational 
hypertension or preeclampsia can be misleading because what might be 
apparently mild disease may progress rapidly to severe disease.
ECLAMPSIA
 Seizures that cannot be attributed to other causes in a woman 
with preeclampsia.
SUPERIMPOSED PREECLAMPSIA ON CHRONIC 
HYPERTENSION:
 New onset proteinuria >300mg/24hours in hypertensive women 
but no proteinuria before 20 weeks gestation.
 A sudden increase in proteinuria or blood pressure or platelet 
count <1,00,000/µl in woman with hypertension & proteinuria 
before 20 weeks gestation.
CHRONIC HYPERTENSION
 BP>140/90mm Hg before pregnancy or diagnosed before 20 
weeks gestation not attributable to gestational trophoblastic   
disease.
                                     (or)
 Hypertension first diagnosed after 20 weeks gestation & 
persistent after 12 weeks postpartum34,35,39.
RISK FACTORS FOR HYPERTENSIVE DISORDERS IN 
PREGNANCY20,21:
Genetic Factors:
 Genetic pre-disposition
 Race & ethnicity- more common in Blacks & Asians
 Family History of preeclampsia
 Pregnancy by ovum donation
Age and parity:
 Teenage pregnancy
 Age more than 40 years
 Long interval between pregnancies
 Nulliparity
Partner related factors:
 Change of partner
 Partner who fathered a pre-eclamptic pregnancy in another 
woman
 Limited sperm exposure
 Pregnancy due to donor insemination
Presence of underlying disorder:
Chronic hypertension
Diabetes mellitus 
Renal disease
Obesity (body mass index > 35kg/m2)
Maternal low birth weight
Polycystic ovarian syndrome
Migraine
Collagen vascular disorders
Uncontrolled hyperthyroidism
Factor V Leiden deficiency
Activated protein C deficiency 
Thrombophilia
Sickle cell disease & other hemoglobinopathies
Antiphospholipid antibodies
 HYPERHOMOCYSTEINEMIA
 Protein S deficiency 
 Women with excessive  snoring
 Previous preterm birth
Pregnancy related risk factor:
 Multiple pregnancies
 Hydatidiform mole
 Hydrops fetalis 
 Congenital & chromosomal fetal anomalies ( Trisomy 13 and 
Triploidy)
 Urinary tract infection
Miscellaneous factors
 Smoking (reduced risk)
 Psychological strain & stress at work place
 Previous history of preeclampsia 
 Raised blood pressure (diastolic >80mm Hg) at booking38,39,45.
PATHOGENESIS
                    Hypertensive disorder of pregnancy continues to be a disease of 
theories & no one theory can explain its etiopathogenesis probably more 
than one theory works. As Boyd stated it remains
                                 “die krankheit der theorien “ 
                                        – The disease of theories.
                       Any satisfactory theory must account for the observation that 
gestational hypertensive disorders are more likely to develop in women who 
42
 Are exposed to chorionic villi for the first time
 Are exposed to super abundance of chorionic villi
 Have preexisting renal or cardio vascular disease
 Are genetically predisposed to hypertension developing during 
pregnancy
                        A fetus is not a requisite for preeclampsia. Although 
chorionic villi are essential, they need not be located within the uterus. The 
cascade of events that lead to preeclampsia syndrome are characterized by a 
host of abnormalities that result in endothelial damage, vasospasm, 
transudation of plasma, ischemic & thrombotic sequeale4,5.
INFLAMMATION
    
                        Pregnancy imposes a substantial systemic inflammatory 
stress on all pregnant women in the second half of pregnancy. The 
inflammatory stimulus may arise from debris shed into maternal circulation 
from the syncytiotrophoblast which if excessive may signal danger to the 
maternal innate immune system8,10.
                        
                       The two stage model of preeclampsia envisages that 
preeclampsia arises in various ways including from placental ischemia 
reperfusion injury secondary to deficient placentation. Poor placentation 
defines the first stage which would appear to have a different origin. The 
first stage decidual immune response account for the primipaternity & 
possible partner specificity of preeclampsia 4, 5.
                   Second stage response all secondary to the systemic 
inflammatory response could also explain why women bearing pregnancies 
with unusually large placenta are susceptible to preeclampsia. 
                     Any factor enhancing this response would predispose to 
preeclampsia.  Indeed recent studies have   shown that not only auto immune 
disorder but also certain maternal infection are involved in the 
etiology15,17,18. 
THE TWO STAGES OF PRE-ECLAMPSIA
sFlt-1 and other syncytiotrophoblast derived 
factors
Stage 2 Second half of 
pregnancy
No symptomsStage 1 First half of 
pregnancy
Poor
Placentation
Overt pre-
eclampsia
Placental oxidative stress 
and inflammation
Maternal systemic 
inflammatory stress
  Clinical signs of
Pre-eclampsia
TWO STAGE THEORY OF PRE-ECLAMPSIA
                 PLACENTAL                                                 MATERNAL
                 PRE-ECLAMPSIA                                         PRE-ECLAMPSIA
High
                ABNORMAL                                                     NORMAL                                                                                                                                            
PLACENTA                                                       PLACENTA
                                            
        Intensity of
                  NORMAL                           systemic         NON-
                  PREGNANCY     inflammatory   PREGNANCY
      Response
                                                                                  (Chronic systemic                         
NON-                                                                               Inflammation)
                PREGNANCY      
                                                                Low
                   
                          The flowchart depicts that in a completely normal woman 
although normal pregnancy stimulates a systemic response, it is not intense 
enough to cause preeclampsia. To do that requires the abnormal stimulus 
from oxidatively stressed placenta (Placental Preeclampsia).In a woman with 
chronic systemic inflammatory response associated condition like chronic 
hypertension, diabetes, etc ,the starting point is abnormal enough that each 
normal placenta can stimulate a systemic response of intensity to cause 
preeclampsia(Maternal Preeclampsia).
ENDOTHELIAL CELL ACTIVATION
                   
                     The endothelium is one of the key organs involved in the 
pathophysiology of preeclampsia as evidenced by the prostacyclin (PGI2) 
thromboxane (TXA2) imbalance, impairment of nitric oxide – cyclic 
guanosine monophosphate pathway & series of markers indicating 
endothelial activation. Glomerular endotheliosis but also ultrastructural 
changes in the placental bed & uterine boundary vessels, provides 
morphologic evidence of endothelial cell injury.  
                     Endothelial cell activation fits the selective platelet activation 
and consumption & the resulting reduction in uteroplacental blood flow due 
to spiral artery thrombosis & placental infarction. Absence of normal 
stimulation of the renin angiotensin system despite relative hypovolemia in 
severe preeclampsia, increased vascular sensitivity to vasoconstrictors & 
increased endothelial cell permeability occur due to endothelial cell 
activation. An inadequate production of PGI2 or NO or increased TXA2 & 
serotonin also occur due to this47, 50, 53, 54.
IMPAIRED CYTOTROPHOBLAST INVASION IN SPIRAL 
ARTERIES 
     
                     In normal pregnancies endovascular cytotrophoblasts replace 
endothelial cells in the spiral arteries, this invasion results in destruction of 
the medial elastic, muscular & neural tissue.  These so called physiologic 
changes normally reach the inner third of the myometrium.    
                   
                      Uterine  natural killer (NK) cells produce a series of cytokines 
involved in angiogenesis and vascular stability including vascular 
endothelial growth factor (VEGF),placental growth factor (PLGF) and 
angiopoietin 2 and play a pivotal role in regulating trophoblastic invasion & 
maternal placental bed vascular changes7,9,23,24,40.
              In hypertensive pregnancies physiologic changes in many but 
not all spiral arteries are confined to the decidual portion of the arteries.  In 
these arteries, the myometrial segments remain anatomically intact, do not 
dilate & the adrenergic nerve supply to the spiral arteries remains intact. 
Acute atherosis characterized by fibrinoid necrosis of vessel wall with an 
accumulation of lipid laden macrophages is commonly seen25,41,44,53.
PRO AND ANTIANGIOGENIC PROTEINS
                 VEGF & PLGF induce vasodilator autacoids including NO & 
PGI2 in endothelial cells & play a major role in pregnancy associated 
vasodilation & increase in GFR. VEGF &PLGF are produced by villous, 
extravillous CTB, STB & decidual leucocytes. The receptors for VEGF fms 
like tyrosine kinase – 1& kinase insert domain containing receptors are both 
expressed on human trophoblast in addition to endothelial cells32,34,35,47.
                                        VEGF is upregulated by hypoxia & provide an 
important mechanism through which the placenta develops according to 
metabolic requirements.  PLGF is downregulated by hypoxia.  sFlt-1, a 
soluble version of VEGF receptor generated by alternative splicing of Flt-1 
gene is a major endogenous angiogenesis inhibitor because it retains the 
ability to bind to VEGF & PLGF while preventing VEGF & PLGF binding 
to cell surface receptors.  The subsequent deficiency of free VEGF & PLGF 
leads to a state of endothelial dysfunction48,49,53.
                       A novel soluble form of endoglin of placental origin present in 
sera of pregnant women is elevated in preeclampsia & amplifies endothelial 
dysfunction.  A recent development was discovery of sFlt-1433,39.
  
IMMUNOLOGICAL BASIS
     
                The invasion of trophoblast into the deciduas & myometrium 
appears to be primarily controlled by immune mechanisms. STB do not 
express HLA antigen. CTB expresses HLA-G & HLA-E.  It was thought 
that HLA-G offered maternal tolerance to fetus through failing to be 
perceived as foreign while still protecting from NK cell mediated 
cytotoxicity34 .
               Decidua predominantly contains NK cells.  NK cells express 
inhibitory and activatory killer cell immunoglobulin like receptors (KIRS) 
capable of recognizing HLA class I molecules.  All women express KIRs on 
decidual NK cells for HLA-C alleles & because HLA-C is polymorphic, 
each pregnancy will involve different combinations of paternally derived 
fetal HLA-C & maternal KIRs .Therefore each pregnancy is based on a 
unique couple specific immune interaction not necessarily involving T cells 
but NK cells interacting with paternal HLA. Mothers belonging to HLA-C2 
group & lacking most or all activating KIRs when fetus has HLA-C are at 
risk of preeclampsia53. 
                
                       
           
           
              Regulatory T cells are also involved in specific immune tolerance.  
Sexual intercourse provokes a cascade of inflammatory response.  TGF-beta 
1 is the critical seminal factor which initiates a type 2 immune response.  
This prevents the induction of type 1 response against semiallogenic   
conceptus   that are associated with poor placental & fetal development35,39. 
PLACENTAL ISCHEMIA/ PLACENTAL DEBRIS HYPOTHESIS 
     
                   Increased deportation of placental tissue in future preeclamptics 
is already detectable at 16 to 18 weeks.  The increased STB deportation is 
explained by the presence of syncytial sprouds that may be elongated on 
long pedicles. Apoptosis plays a central role in the formation of STB from 
underlying villous CTB. Apoptosis is increased in preeclampsia.  
                        The maternal inflammatory response is the likely cause of the 
increased apoptosis.  In earlier stages, increased apoptosis is caused by TNF, 
INF-gamma, FAS ligand later on caused by placental ischemia, 
reperfusion33,42,43.
GENETIC CONFLICT HYPOTHESIS
                   According to Haigs genetic conflict theory fetal genes will be 
selected to increase the transfer of nutrients to the fetus and maternal genes 
will be selected to limit transfers. Genomic imprinting means that within 
fetal cells a similar conflict exists between genes that are maternally derived 
& genes that are paternally derived28,30.  Placental factors (fetal genes) will 
act to increase maternal BP whereas maternal factors will act to reduce BP.  
This theory predicts that fetal genes will enhance flow of maternal blood 
through the intervillous space by increasing maternal BP (perfusion 
pressure)51,52,53.
PREDICTION OF HYPERTENSION IN PREGNANCY
                    A review of world literature reveals that more than 100 clinical, 
biophysical & biochemical tests have been recommended to predict or 
identify the patient at risk.  The results of the pooled data for the various 
tests & the lack of agreement between serial tests suggest that none of these 
clinical tests is sufficiently reliable for use as screening.
                   
                  
                 The biochemical markers were generally chosen on the basis of 
specific pathophysiologic abnormalities that cause preeclampsia. Hence 
markers of placental dysfunction, endothelial & coagulation activation, 
angiogenesis & systemic inflammation are used. The research in this aspect 
is still going on27,31,32.
   
PREVENTIVE ASPECTS 
      
                        There are numerous clinical trials describing the use of 
various methods to prevent or reduce the incidence of preeclampsia. Because 
the etiology of the disease is unknown these interventions have been used in 
an attempt to correct theoretical abnormalities35,36,37. In short randomized 
trials have evaluated protein, salt restriction, zinc, magnesium, fish oil, 
antioxidant supplementation, use of aspirin, heparin to prevent hypertension 
is pregnancy.
HOMOCYSTEINE 
 Homocysteine is a non protein sulphur containing amino acid 
with the formula HSCH2 CH2 CH (NH2) CO2H.
 Homologue of the amino acid cysteine differing by an 
additional methylene group.
 It is biosynthesized from methionine by removal of terminal C 
methyl group
 It can be recycled into methionine or converted to cysteine. 
 It exists at neutral PH values as zwitterions55,56. 
BIOSYNTHESIS & BIOCHEMICAL ROLES
                   Homocysteine is not obtained from the diet. Instead it is 
biosynthesized from methionine in a multiple step process. First methionine 
receives an adenosine group from ATP, a reaction catalyzed by adenosyl 
methionine synthetase to give rise to s-adenosyl methionine. SAM then 
transfers the methyl group to an acceptor molecule. The adenosine is then 
hydrolyzed to yield L-Homocysteine .L- Homocysteine has two primary 
fates.
1. Conversion to L-methionine
2. Conversion to L-cysteine59,60,61
BIOSYNTHESIS & BIOCHEMICAL ROLES  OF HOMOCYSTEINE
BIOSYNTHESIS OF CYSTEINE
               
                Mammals biosynthesis the amino acid cysteine via Homocysteine.  
Cystathionine beta synthase catalyses the condensation of Homocysteine & 
serine to give Cystathionine. This reaction uses pyridoxine (vit B6) as a 
cofactor. Cystathionine beta lyase then converts this double amino acid to 
cysteine, ammonia & alpha ketobutyrate.
METHIONOINE SALVAGE
                Homocysteine is remethylated by methyl tetrahydrofolate 
catalyzed by methionine synthase, a vitamin B12 dependent enzyme.
FOLATE TRAP
           
                As the reduction of methylene tetrahydrofolate to methyl 
tetrahydrofolate is irreversible & the major source of tetrahydrofolate for the 
tissues is methyl THF, the role of methionine synthase is vital & provides 
the link between the functions of folate and vitamin B12. Impairment of 
methionine synthase in vitamin B12 deficiency results in the accumulation 
of methyl THF- the folate  trap59,60,61.
                   As depicted above the enzyme MTHFR is essential to convert 5, 
10, methylene THF to methyl THF which is essential for conversion of 
homocysteine into methionine.
FOLATE TRAP
RISKS OF HYPERHOMOCYSTEINEMIA
                     Homocysteine degrades & inhibits the formation of the three 
main structural components of the artery- collagen, elastin and 
proteoglycans. It permanently degrades cysteine disulphide bridges & lysine 
amino acid residues in proteins gradually affecting function and structure.  
Simply put it is a ‘corrosive’ of long living proteins.  It is linked to high 
concentrations of endothelial asymmetric dimethylarginine which causes 
endothelial dysfunction 22,26.
                        Homocysteine injures endothelial lining of arteries and 
stimulates the growth of smooth muscle cells. Excess homocysteine can 
form homocysteine thiolactone, a highly reactive intermediate which 
thiolates free amino groups in LDL & causes them to aggregate and be 
endocytosed   by  macrophages.   The lipid   deposits form atheromas.     It 
causes lipid oxidation & platelet aggregation. It inhibits NO indirectly by 
stimulating   superoxide anion production from endothelial cells. It 
enhances atherogenicity of LP(a) by liberating free Apo(a) & in turn 
inhibits fibrinolysis. It is atherogenic & thrombophilic. Elevated 
homocysteine  levels   are  implicated in   coronary,   cerebrovascular    &
peripheral arterial disease, DVT, neural tube defects in fetus and 
preeclampsia57,58. 
HYPERHOMOCYSTEINEMIA
                    Elevations of Homocysteine are associated with defects in 3 
genes
1. Cystathionine Beta synthase
2. MTHFR
3. Methionine synthase
                     Of these the first two are clinically important. CBS gene 
defects leads to hyperhomocysteinemia & homocystinuria. MTHFR gene 
defects lead only to hyperhomocysteinemia. Heterozygotes do not have any 
manifestations. Homozygotes have clinical manifestations. The thermolabile 
variant of MTHFR is quite common.
           
                     It   is also raised in early cobalamin & folate deficiency, 
chronic renal disease, alcoholism, smoking, vit B6 deficiency, 
hypothyroidism, therapy with steroids, cyclosporine.  Levels are also     
higher in serum than in plasma, in men than in women, in women on 
HRT/OCP, in elderly persons55,56.
PLASMA HOMOCYSTEINE LEVELS
NORMAL           -                5-15 µmol/L
HYPERHOMOCYSTEINEMIA
MILD                  -               15-25 µmol/L
MODERATE      -               25-50 µmol/L
SEVERE             -                >50 µmol/L
                      
                                                  Noto et al62(2003) conducted a study in 
which Homocysteine levels were determined with chromatography on 
HPLC between the 20th & 24th week of pregnancy in women with analogous 
characteristics a) normotensive, b) with pregnancy induced hypertension, 
low, medium, high risk. Risk group was based on classification adopted by 
World Health Organization based on pressure data & coexistence of risk 
factors. The group they belonged to was confirmed after delivery. 
Homocysteine   levels in   normotensive  pregnant  women   were       low.
Significant high levels of homocysteine present proportionally to  the    risk 
degree of PIH. Higher levels of Homocysteine statistically significant were 
present in all risk groups.
     
                     Steegers Theunissen et al 68 (2004) conducted a study to assess 
associations between vitamin dependent Homocysteine metabolism and 
vascular related pregnancy complications by considering interval between 
delivery and postpartum investigation and maternal age. It was found 
hyperhomocysteinemia was associated with an approximately 2 fold to 3 
fold increased risk for PIH, abruption & IUGR. Cobalamin deficiency was 
associated with HELLP syndrome, abruptio placenta, IUGR & IUD. 
Pyridoxal 5 phosphate deficiency increased risk of PIH. These associations 
lost the significance after adjustment for time interval & maternal age. High 
red cell folate was associated with a decreased risk for abruptio placentae 
and IUGR. An increased creatinine concentration was associated with PIH, 
preeclampsia, HELLP & abruption.
                  
                      El abd et al 69(2009) determined the association between 
plasma homocysteine level and early onset severe preeclampsia and its 
relevance as a potential marker for predicting preeclampsia. Case control 
study was conducted on twenty early onset severe preeclamptic pregnant 
women    and 10 normotensive pregnant women as controls. It was found 
that plasma homocysteine significantly increased in early onset severe 
preeclampsia and it might contribute in the pathophysiology of the disease
     
                       Vincent et al71 (2009) conducted a study in Nigeria. A total of 
150 subjects consisting of 100 primigravidae & 25 diagnosed cases of pre-
eclampsia/eclampsia and 25 non pregnant females were enrolled in the 
study. There was positive and significant correlation between plasma 
homocysteine in the eclamptic group & mean MCV & between plasma 
homocysteine, systolic & diastolic blood pressure of the eclamptic group.
                     Raijmakers et al63(2001) investigated the role of 
Hyperhomocysteinemia in preeclampsia by measuring plasma levels of   
homocysteine and studying the prevalence of 677(C->T) polymorphism in 
the 5-10 MTHFR gene. Plasma samples of 10 healthy non pregnant women, 
10 normotensive pregnant women & 20 women with preeclampsia were 
analysed for homocysteine levels. 
                        Furthermore 167 non pregnant women previously 
hospitalized for preeclampsia and 403 population based controls were 
analyzed for 677(C->T) polymorphism. It was found in normotensive 
pregnancy  homocysteine   levels  were  lower  compared   with levels  in 
healthy non pregnant controls .Women with preeclampsia showed higher 
concentration of homocysteine. There was no difference in 677(C->T) 
polymorphism in preeclampsia and normal women.
                  
                       Powers et al64 (2001) conducted a study to confirm that 
endothelial dysfunction is present in preeclampsia and absent in transient 
hypertension of pregnancy & to determine whether homocysteine is 
associated with the degree of  endothelial dysfunction in 17 women with 
preeclampsia, 16 women with transient hypertension of pregnancy & 34 
normal pregnant women. It was concluded that cellular fibronectin was 
found to be significantly increased in women with preeclampsia compared to 
subjects with transient hypertension of pregnancy or normal pregnant 
women. Similarly plasma homocysteine was also significantly increased in 
women with preeclampsia compared to others. There was no apparent 
association between cellular fibronectin and homocysteine.
                    
                         Sanchez et al65(2001) measured maternal third trimester 
plasma folate, vitamin B12 and homocysteine concentration among 125 
women with preeclampsia and 179 normotensive women. It was found that 
lower levels of folate, higher   levels of homocysteine   were    associated 
with preeclampsia. There was no association between low vitamin B12 
levels and preeclampsia.
                 
                    Lopez et al67 (2003) conducted a study to determine possible 
association between hyperhomocysteinemia and preeclampsia. It was a case 
control study with 32 preeclamptics and 64 controls without pregnancy 
complications .Plasma total homocysteine determined by HPLC. Pregnant 
women with hyperhomocysteinemia have a 7.7 fold risk for preeclampsia 
was the conclusion arrived.
Materials and Methods
MATERIALS AND METHODS
                               Our study was a case control study. The cases of our 
study were postnatal patients who had gestational hypertension. The controls 
were postnatal patients who were comparable with the patients’ groups with 
regard to social class, geographical area and age. They were friends or 
acquaintances of the patients and had uncomplicated pregnancies. 
          
                   From October 2009 to November 2010 our study was conducted 
in the department of Obstetrics and Gynaecology, Coimbatore medical 
college hospital, Coimbatore on 111 patients. Gestational hypertension was 
defined as systolic BP> 140mm Hg & diastolic BP> 90mm Hg detected for 
the first time during pregnancy after 20 weeks of gestation.  Preeclampsia 
was defined as gestational hypertension with proteinuria. Eclampsia defined 
as seizures that cannot be attributed to other causes in a woman with 
preeclampsia. Proteinuria is defined as >1+ dipstick.
                   
                  For the measurement of BP, conventional sphygmomanometer 
was used.  BP was measured after it was made sure that the women were 
relaxed & resting for at least half an hour before blood pressure 
measurement. It was measured in the sitting position with the forearm 
horizontal & well supported and the upper arm at the level of the heart.  The 
cuff was long enough to encircle the arm and wide enough to cover at least 
two thirds of the upper arm. The disappearance of korotkoff phase V was 
used to define diastolic pressure. Two measurements at least 6 hours apart 
were taken. Mean arterial pressure is defined as systolic BP + 2/3 diastolic 
BP.
              
                     All participants were explained about the study and consent 
was obtained. After exclusion of users of vitamin B, folic acid, 
pharmacologic agents, restricted diets, women with disorder like chronic 
hypertension, diabetes mellitus, gastrointestinal, endocrine disorder, twin 
pregnancies, the study group consisted of 50 cases & 61 controls. Of the 
cases 16 had gestational hypertension, 26 had preeclampsia and 8 had 
Eclampsia. Controls had uncomplicated obstetric histories. The participants 
were subjected to detailed history elicitation & physical examination.
              
                        Peripheral blood sample was obtained from all participants in 
fasting state. The samples kept in cooled down polyethylene test tube 
containing EDTA (5µM/ml of blood) were immediately put into a freezer at 
-20 degree C, later to be used in dosing homocysteine. The blood sample 
was obtained within a day of delivery. The dosage of plasma homocysteine 
was carried out with Chemi luminescence immunoassay method. The 
normal range was between 5 and 15 µmol/L. 
Results and Analysis
DISTRIBUTION OF SYSTOLIC BLOOD   PRESSURE 
BETWEEN NORMAL MOTHERS AND MOTHERS WITH 
GESTATIONAL HYPERTENSION
                   The figure shows that mean SBP in normal mother
119.67mmHg, in mothers with gestational hypertension is 139.38mmHg, in 
preeclampsia is 151.69mmHg and in Eclampsia is 169.25mmHg.
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DISTRIBUTION OF DIASTOLIC BLOOD   PRESSURE 
BETWEEN NORMAL MOTHERS AND MOTHERS WITH 
GESTATIONAL HYPERTENSION
                        The figure shows that mean DBP in normal mothers is 80.16 
mmHg, in mothers with gestational hypertension is 98.13 mmH
preeclampsia is 98.38 mmHg and in Eclampsia is 107.75 mmHg.
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DISTRIBUTION OF MEAN ARTERIAL PRESSURE 
BETWEEN NORMAL MOTHERS AND MOTHERS WITH 
GESTATIONAL HYPERTENSION
                     
                     The figure shows that mean M
mmHg, in mothers with gestational hypertension is 111.88 mmHg, in 
preeclampsia is 118.72 mmHg and in Eclampsia is 128.25mmHg.
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DISTRIBUTION OF AGE BETWEEN NORMAL MOTHERS 
AND MOTHERS WITH GESTATIONAL HYPERTENSION
                      The figure shows that mean age in normal mothers is  23.21 
years, in mothers with gestational hypertension is 24.44 years, in 
preeclampsia is 24.42 years and in Eclampsia is  22 years
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DISTRIBUTION OF PLASMA HOMOCYSTEINE 
BETWEEN NORMAL MOTHERS AND MOTHERS WITH 
GESTATIONAL HYPERTENSION
                       
                  The figure shows that mean plasma homocysteine in normal 
mothers is 10.50µmol/L, in mothers with gestational hyperten
16.43µmol/L, in preeclampsia is 20.23µmol/L and in Eclampsia is 
20.10µmol/L.
0
5
10
15
20
25
Normal 
Mothers
Mothers with 
Gestational 
Hypertension
Plasma Homocysteine
FIGURE-5
Pre-Eclampsia Eclampsia
Plasma 
Homocysteine
sion is 
FIGURE-6
DISTRIBUTION OF AGE
                    
                     It is inferred from the figure that of the total 111 participants 84 
of them are in the age group < 25 years, 22 of them are in the age group 
between 25-30 years and 5 of them are in the age group above 30 years.
No. of Mothers
Less than 25 
years
Between 25 - 30 
years
Above 30 years
ASSOCIATION BETWEEN FAMILY HISTORY OF 
CARDIOVASCULAR DISEASE AND GESTATIONAL 
                    The figure depicts that positive family history of cardiovascular 
disease is found more in mothers with gestational hypertension, 
preeclampsia and Eclampsia than in normal mothers.
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TABLE-1
                         
                     The table shows the minimum, maximum, mean and standard 
deviation values of all variables.
    DESCRIPTIVE STATISTICS
111 18 38 23.59 3.602
111 110 180 133.59 17.666
111 70 130 89.01 15.523
111 83.33 176.67 104.4685 15.07492
111 1.40 3.70 2.8080 .34712
111 6 54 14.32 7.899
111
Age
SBP
DBP
Mean Arterial Pressure
Birth Weight of Child
P.Homocysteine
Valid N (list wise)
N Minimum Maximum Mean Std. Deviation
TABLE-2
ASSOCIATION BETWEEN AGE AND GESTATIONAL 
HYPERTENSION
                    The Chi square value of age and gestational hypertension is 
5.160 and p= 0.523, so it can be inferred that there is no association between 
the two.
48 11 18 7 84
57.1% 13.1% 21.4% 8.3% 100.0%
78.7% 68.8% 69.2% 87.5% 75.7%
12 3 6 1       22
54.5% 13.6% 27.3% 4.5% 100.0%
19.7% 18.8% 23.1% 12.5% 19.8%
1 2 2 0 5
20.0% 40.0% 40.0% .0% 100.0%
1.6% 12.5% 7.7% .0% 4.5%
61 16 26 8 111
55.0% 14.4% 23.4% 7.2% 100.0%
100.0% 100.0% 100.0% 100.0% 100.0%
Count
% within Age
% within Diagnosis
Count
% within Age
% within Diagnosis
Count
% within Age
% within Diagnosis
Count
% within Age
% within Diagnosis
Less than 25 years
Between 25 - 30 years
Above 30 years
Age
Total
Normal
Gestational
Hypertension
Pre
Eclampsia Eclampsia
Diagnosis
Total
TABLE-3
ASSOCIATION BETWEEN PARITY AND GESTATIONAL 
HYPERTENSION
                        
                        The Chi square value of parity and gestational hypertension is 
11.713 and p= 0.230, so it can be inferred that there is no association 
between the two.
32 11 16 7 66
48.5% 16.7% 24.2% 10.6% 100.0%
52.5% 68.8% 61.5% 87.5% 59.5%
25 5 5 1 36
69.4% 13.9% 13.9% 2.8% 100.0%
41.0% 31.3% 19.2% 12.5% 32.4%
3 0 4 0 7
42.9% .0% 57.1% .0% 100.0%
4.9% .0% 15.4% .0% 6.3%
1 0 1 0 2
50.0% .0% 50.0% .0% 100.0%
1.6% .0% 3.8% .0% 1.8%
61 16 26 8 111
55.0% 14.4% 23.4% 7.2% 100.0%
100.0% 100.0% 100.0% 100.0% 100.0%
Count
% within Parity
% within Diagnosis
Count
% within Parity
% within Diagnosis
Count
% within Parity
% within Diagnosis
Count
% within Parity
% within Diagnosis
Count
% within Parity
% within Diagnosis
One
Two
Three
Four
Parity
Total
Normal
Gestational
Hypertension
Pre
Eclampsia Eclampsia
Diagnosis
Total
TABLE-4
ASSOCIATION BETWEEN No. OF LIVE BIRTHS AND 
GESTATIONAL HYPERTENSION
              
                    The Chi square value of no of live births and gestational 
hypertension is 23.286 and p< 0.05, so it can be inferred that there is an 
association between the two.
0 3 1 2 6
.0% 50.0% 16.7% 33.3% 100.0%
.0% 18.8% 3.8% 25.0% 5.4%
33 7 17 5 62
53.2% 11.3% 27.4% 8.1% 100.0%
54.1% 43.8% 65.4% 62.5% 55.9%
24 4 4 1 33
72.7% 12.1% 12.1% 3.0% 100.0%
39.3% 25.0% 15.4% 12.5% 29.7%
3 2 3 0 8
37.5% 25.0% 37.5% .0% 100.0%
4.9% 12.5% 11.5% .0% 7.2%
1 0 1 0 2
50.0% .0% 50.0% .0% 100.0%
1.6% .0% 3.8% .0% 1.8%
61 16 26 8 111
55.0% 14.4% 23.4% 7.2% 100.0%
100.0% 100.0% 100.0% 100.0% 100.0%
Count
% within Live
% within Diagnosis
Count
% within Live
% within Diagnosis
Count
% within Live
% within Diagnosis
Count
% within Live
% within Diagnosis
Count
% within Live
% within Diagnosis
Count
% within Live
% within Diagnosis
Nil
One
Two
Three
Four
Live
Total
Normal
Gestational
Hypertension
Pre
Eclampsia Eclampsia
Diagnosis
Total
TABLE-5
ASSOCIATION BETWEEN No. OF ABORTIONS AND 
GESTATIONAL HYPERTENSION
                      The Chi square value of no of abortions and gestational 
hypertension is 6.426 and p= 0.377, so it can be inferred that there is no 
association between the two.
58 15 21 7 101
57.4% 14.9% 20.8% 6.9% 100.0%
95.1% 93.8% 80.8% 87.5% 91.0%
3 1 4 1 9
33.3% 11.1% 44.4% 11.1% 100.0%
4.9% 6.3% 15.4% 12.5% 8.1%
0 0 1 0 1
.0% .0% 100.0% .0% 100.0%
.0% .0% 3.8% .0% .9%
61 16 26 8 111
55.0% 14.4% 23.4% 7.2% 100.0%
100.0% 100.0% 100.0% 100.0% 100.0%
Count
% within Abortion
% within Diagnosis
Count
% within Abortion
% within Diagnosis
Count
% within Abortion
% within Diagnosis
Count
% within Abortion
% within Diagnosis
Nil
One
Two
Abortion
Total
Normal
Gestational
Hypertension
Pre
Eclampsia Eclampsia
Diagnosis
Total
TABLE-6
ASSOCIATION BETWEEN MATERNAL BLOOD GROUPS 
AND GESTATIONAL HYPERTENSION
                  The Chi square value of maternal blood groups and gestational 
hypertension is 10.099 and p= 0.343, so it can be inferred that there is no 
association between the two.
19 6 8 1 34
55.9% 17.6% 23.5% 2.9% 100.0%
31.1% 37.5% 30.8% 12.5% 30.6%
16 7 8 4 35
45.7% 20.0% 22.9% 11.4% 100.0%
26.2% 43.8% 30.8% 50.0% 31.5%
26 2 9 3 40
65.0% 5.0% 22.5% 7.5% 100.0%
42.6% 12.5% 34.6% 37.5% 36.0%
0 1 1 0 2
.0% 50.0% 50.0% .0% 100.0%
.0% 6.3% 3.8% .0% 1.8%
61 16 26 8 111
55.0% 14.4% 23.4% 7.2% 100.0%
100.0% 100.0% 100.0% 100.0% 100.0%
Count
% within Blood Group
% within Diagnosis
Count
% within Blood Group
% within Diagnosis
Count
% within Blood Group
% within Diagnosis
Count
% within Blood Group
% within Diagnosis
Count
% within Blood Group
% within Diagnosis
O+ve
B+ve
A+ve
AB+ve
Blood
Group
Total
Normal
Gestational
Hypertension
Pre
Eclampsia Eclampsia
Diagnosis
Total
TABLE-7
ASSOCIATION BETWEEN FAMILY HISTORY OF 
CARDIOVASCULAR DISEASE AND GESTATIONAL 
HYPERTENSION
                     The Chi square value of family history of cardiovascular 
disease and gestational hypertension is 19.533 and p< 0.001, so it can be 
inferred that there is an association between the two.
58 13 15 5 91
63.7% 14.3% 16.5% 5.5% 100.0%
95.1% 81.3% 57.7% 62.5% 82.0%
3 3 11 3 20
15.0% 15.0% 55.0% 15.0% 100.0%
4.9% 18.8% 42.3% 37.5% 18.0%
61 16 26 8 111
55.0% 14.4% 23.4% 7.2% 100.0%
100.0% 100.0% 100.0% 100.0% 100.0%
Count
% within Family History
% within Diagnosis
Count
% within Family History
% within Diagnosis
Count
% within Family History
% within Diagnosis
No
Yes
Family
History
Total
Normal
Gestational
Hypertension
Pre
Eclampsia Eclampsia
Diagnosis
Total
TABLE-8
ASSOCIATION BETWEEN SEX OF CHILD AND 
GESTATIONAL HYPERTENSION
                   The Chi square value of sex of child and gestational 
hypertension is 2.388 and p=0.496, so it can be inferred that there is no 
association between the two.
33 10 17 3 63
52.4% 15.9% 27.0% 4.8% 100.0%
54.1% 62.5% 65.4% 37.5% 56.8%
28 6 9 5 48
58.3% 12.5% 18.8% 10.4% 100.0%
45.9% 37.5% 34.6% 62.5% 43.2%
61 16 26 8 111
55.0% 14.4% 23.4% 7.2% 100.0%
100.0% 100.0% 100.0% 100.0% 100.0%
Count
% within Child Sex
% within Diagnosis
Count
% within Child Sex
% within Diagnosis
Count
% within Child Sex
% within Diagnosis
Male
Female
Child Sex
Total
Normal
Gestational
Hypertension
Pre
Eclampsia Eclampsia
Diagnosis
Total
TABLE-9
ASSOCIATION BETWEEN BIRTH WEIGHT OF CHILD AND 
GESTATIONAL HYPERTENSION
                      
                     The Chi square value of birth weight of child and gestational 
hypertension is 11.389 and p=0.077, so it can be inferred that there is no 
association between the two.
19 5 3 0 27
70.4% 18.5% 11.1% .0% 100.0%
31.1% 31.3% 11.5% .0% 24.3%
28 9 20 7 64
43.8% 14.1% 31.3% 10.9% 100.0%
45.9% 56.3% 76.9% 87.5% 57.7%
14 2 3 1 20
70.0% 10.0% 15.0% 5.0% 100.0%
23.0% 12.5% 11.5% 12.5% 18.0%
61 16 26 8 111
55.0% 14.4% 23.4% 7.2% 100.0%
100.0% 100.0% 100.0% 100.0% 100.0%
Count
% within Weight
% within Diagnosis
Count
% within Weight
% within Diagnosis
Count
% within Weight
% within Diagnosis
Count
% within Weight
% within Diagnosis
Less than 2.5 Kg
2.5 - 3 Kg
Above 3 Kg
Weight
Total
Normal
Gestational
Hypertension
Pre
Eclampsia Eclampsia
Diagnosis
Total
TABLE-10
ASSOCIATION BETWEEN PLASMA HOMOCYSTEINE AND 
GESTATIONAL HYPERTENSION
                      
                      The Chi square value of plasma homocysteine and gestational 
hypertension is 40.954 and p<0.001, so it can be inferred that there is an 
association between the two.
57 8 9 2 76
75.0% 10.5% 11.8% 2.6% 100.0%
93.4% 50.0% 34.6% 25.0% 68.5%
4 8 17 6 35
11.4% 22.9% 48.6% 17.1% 100.0%
6.6% 50.0% 65.4% 75.0% 31.5%
61 16 26 8 111
55.0% 14.4% 23.4% 7.2% 100.0%
100.0% 100.0% 100.0% 100.0% 100.0%
Count
% within Plasma
Homocysteine
% within Diagnosis
Count
% within Plasma
Homocysteine
% within Diagnosis
Count
% within Plasma
Homocysteine
% within Diagnosis
Normal
Abnormal
Plasma Homocysteine
Total
Normal
Gestational
Hypertension
Pre
Eclampsia Eclampsia
Diagnosis
Total
TABLE-11
CORRELATION BETWEEN   FACTORS
                                  
      
**correlation is significant at the 0.01 level 
              
                    The table depicts the positive correlation between Family 
history of cardiovascular disease, SBP, DBP, MAP and plasma 
homocysteine.
Parity
Family 
History
MAP SBP DBP
P.Homocys
teine
Parity
Pearson correlation(r)
Significance(p)
N.
1
111
098
.306
111
.042
.663
111
.089
.353
111
.111
.244
111
.010
.919 
111
Family 
History
Pearson correlation(r)
Significance(p)
N.
.098
.306
111
1
111
.360**
.000
111
438**
.000
111
.276**
.003
111
.181
.058
111
MAP
Pearson correlation(r)
Significance(p)
N.
042
.663
111
.360**
.000
111
1
111
.872**
.000
111
.960**
.000
111
.
.447**
.000
111
SBP
Pearson correlation(r)
Significance(p)
N.
.089
.353
111
438**
.000
111
.872**
.000
111
1
111
.701**
.000
111
.559**
.000
111
DBP
Pearson correlation(r)
Significance(p)
N.
.111
.244
111
.276**
.003
111
.960**
.000
111
.
.701**
.000
111
1
111
.334**
.000
111
P.Homocy
steine
Pearson correlation(r)
Significance(p)
N.
010
.919 
111
.181
.058
111
.477**
.000
111
.559**
.000
111
.334**
.000
111
1
111
               
TABLE-12
ASSOCIATION BETWEEN AGE AND PLASMA 
HOMOCYSTEINE
                     The chi square value of age and plasma homocysteine is 0.323 
and p=0.851, so it can be inferred that there is no association between the 
two.
57 27 84
67.9% 32.1% 100.0%
75.0% 77.1% 75.7%
15 7 22
68.2% 31.8% 100.0%
19.7% 20.0% 19.8%
4 1 5
80.0% 20.0% 100.0%
5.3% 2.9% 4.5%
76 35 111
68.5% 31.5% 100.0%
100.0% 100.0% 100.0%
Count
% within Age
% within Plasma
Homocysteine
Count
% within Age
% within Plasma
Homocysteine
Count
% within Age
% within Plasma
Homocysteine
Count
% within Age
% within Plasma
Homocysteine
Less than 25 years
Between 25 - 30 years
Above 30 years
Age
Total
Normal Abnormal
Plasma Homocysteine
Total
TABLE-13
ASSOCIATION BETWEEN PARITY AND PLASMA 
HOMOCYSTEINE
                       
                      The chi square value of parity and plasma homocysteine is 
2.385 and p=0.496, so it can be inferred that there is no association between 
the two.
43 23 66
65.2% 34.8% 100.0%
56.6% 65.7% 59.5%
27 9 36
75.0% 25.0% 100.0%
35.5% 25.7% 32.4%
4 3 7
57.1% 42.9% 100.0%
5.3% 8.6% 6.3%
2 0 2
100.0% .0% 100.0%
2.6% .0% 1.8%
76 35 111
68.5% 31.5% 100.0%
100.0% 100.0% 100.0%
Count
% within Parity
% within Plasma
Homocysteine
Count
% within Parity
% within Plasma
Homocysteine
Count
% within Parity
% within Plasma
Homocysteine
Count
% within Parity
% within Plasma
Homocysteine
Count
% within Parity
% within Plasma
Homocysteine
One
Two
Three
Four
Parity
Total
Normal Abnormal
Plasma Homocysteine
Total
TABLE-14
ASSOCIATION BETWEEN No. OF LIVE BIRTHS AND 
PLASMA HOMOCYSTEINE
                     The chi square value of no of live births and plasma 
homocysteine is 7.066 and p=0.132, so it can be inferred that there is no 
association between the two.
3 3 6
50.0% 50.0% 100.0%
3.9% 8.6% 5.4%
42 20 62
67.7% 32.3% 100.0%
55.3% 57.1% 55.9%
26 7 33
78.8% 21.2% 100.0%
34.2% 20.0% 29.7%
3 5 8
37.5% 62.5% 100.0%
3.9% 14.3% 7.2%
2 0 2
100.0% .0% 100.0%
2.6% .0% 1.8%
76 35 111
68.5% 31.5% 100.0%
100.0% 100.0% 100.0%
Count
% within Live
% within Plasma
Homocysteine
Count
% within Live
% within Plasma
Homocysteine
Count
% within Live
% within Plasma
Homocysteine
Count
% within Live
% within Plasma
Homocysteine
Count
% within Live
% within Plasma
Homocysteine
Count
% within Live
% within Plasma
Homocysteine
Nil
One
Two
Three
Four
Live
Total
Normal Abnormal
Plasma Homocysteine
Total
TABLE-15
ASSOCIATION BETWEEN No. OF ABORTIONS AND 
PLASMA HOMOCYSTEINE
                        The chi square value of no of abortions and plasma 
homocysteine is 3.023 and p=0.221, so it can be inferred that there is no 
association between the two.
71 30 101
70.3% 29.7% 100.0%
93.4% 85.7% 91.0%
5 4 9
55.6% 44.4% 100.0%
6.6% 11.4% 8.1%
0 1 1
.0% 100.0% 100.0%
.0% 2.9% .9%
76 35 111
68.5% 31.5% 100.0%
100.0% 100.0% 100.0%
Count
% within Abortion
% within Plasma
Homocysteine
Count
% within Abortion
% within Plasma
Homocysteine
Count
% within Abortion
% within Plasma
Homocysteine
Count
% within Abortion
% within Plasma
Homocysteine
Nil
One
Two
Abortion
Total
Normal Abnormal
Plasma Homocysteine
Total
TABLE-16
ASSOCIATION BETWEEN MATERNAL BLOOD GROUPS 
AND PLASMA HOMOCYSTEINE
                     The chi square value of maternal blood groups and plasma 
homocysteine is 5.360 and p=0.147, so it can be inferred that there is no 
association between the two.
20 14 34
58.8% 41.2% 100.0%
26.3% 40.0% 30.6%
22 13 35
62.9% 37.1% 100.0%
28.9% 37.1% 31.5%
32 8 40
80.0% 20.0% 100.0%
42.1% 22.9% 36.0%
2 0 2
100.0% .0% 100.0%
2.6% .0% 1.8%
76 35 111
68.5% 31.5% 100.0%
100.0% 100.0% 100.0%
Count
% within Blood Group
% within Plasma
Homocysteine
Count
% within Blood Group
% within Plasma
Homocysteine
Count
% within Blood Group
% within Plasma
Homocysteine
Count
% within Blood Group
% within Plasma
Homocysteine
Count
% within Blood Group
% within Plasma
Homocysteine
O+ve
B+ve
A+ve
AB+ve
Blood Group
Total
Normal Abnormal
Plasma Homocysteine
Total
TABLE-17
ASSOCIATION BETWEEN FAMILY HISTORY OF 
CARDIOVASCULAR DISEASE AND PLASMA 
HOMOCYSTEINE
                        The chi square value of family history of cardiovascular 
disease and plasma homocysteine is 3.854 and p<0.05, so it can be inferred 
that there is an association between the two.
66 25 91
72.5% 27.5% 100.0%
86.8% 71.4% 82.0%
10 10 20
50.0% 50.0% 100.0%
13.2% 28.6% 18.0%
76 35 111
68.5% 31.5% 100.0%
100.0% 100.0% 100.0%
Count
% within Family History
% within Plasma
Homocysteine
Count
% within Family History
% within Plasma
Homocysteine
Count
% within Family History
% within Plasma
Homocysteine
No
Yes
Family
History
Total
Normal Abnormal
Plasma Homocysteine
Total
TABLE-18
ASSOCIATION BETWEEN SEX OF CHILD AND PLASMA 
HOMOCYSTEINE
                        The Chi square value of sex of child and plasma 
homocysteine is 0.127 and p=0.721, so it can be inferred that there is no 
association between the two.
44 19 63
69.8% 30.2% 100.0%
57.9% 54.3% 56.8%
32 16 48
66.7% 33.3% 100.0%
42.1% 45.7% 43.2%
76 35 111
68.5% 31.5% 100.0%
100.0% 100.0% 100.0%
Count
% within Child Sex
% within Plasma
Homocysteine
Count
% within Child Sex
% within Plasma
Homocysteine
Count
% within Child Sex
% within Plasma
Homocysteine
Male
Female
Child Sex
Total
Normal Abnormal
Plasma Homocysteine
Total
TABLE-19
ASSOCIATION BETWEEN BIRTH WEIGHT OF CHILD AND 
PLASMA HOMOCYSTEINE
                    The Chi square value of birth weight of child and plasma 
homocysteine is 8.093 and p<0.01, so it can be inferred that there is an 
association between the two.
23 4 27
85.2% 14.8% 100.0%
30.3% 11.4% 24.3%
37 27 64
57.8% 42.2% 100.0%
48.7% 77.1% 57.7%
16 4 20
80.0% 20.0% 100.0%
21.1% 11.4% 18.0%
76 35 111
68.5% 31.5% 100.0%
100.0% 100.0% 100.0%
Count
% within Weight
% within Plasma
Homocysteine
Count
% within Weight
% within Plasma
Homocysteine
Count
% within Weight
% within Plasma
Homocysteine
Count
% within Weight
% within Plasma
Homocysteine
Less than 2.5 Kg
2.5 - 3 Kg
Above 3 Kg
Weight
Total
Normal Abnormal
Plasma Homocysteine
Total
Discussion
DISCUSSION
                     Our study was conducted in the Department  of   Obstetrics 
and Gynaecology, Coimbatore Medical College hospital ,Coimbatore,  of 
Tamilnadu Dr M.G.R. Medical university with the aim of  finding  a  
relationship between plasma  homocysteine  levels  and   gestational 
hypertension with 111 participants.
                      The results were expressed as means, standard deviation. For 
groups chi square test and the student t test were used. Pearson co-relation 
coefficient was used to detect the correlation between different variables. 
The level of significance was 0.05. 
                        The mean age in the control group was 23.21 years, in 
mothers   with   gestational  hypertension was 24.44 years, in preeclampsia 
was 24.42 years   and in Eclampsia was 22 years as shown in figure-4. 
There  was  no significant  difference  between  the  groups  as  regards  
women’s  age  . The mean SBP in normal mothers was 119.67mmHg, in 
mothers with gestational hypertension was 139.38mmHg, in preeclampsia 
was 151.69mmHg and in Eclampsia was 169.25mmHg as shown in figure-
1.The mean DBP in normal mothers was 80.16 mmHg, in mothers with 
gestational hypertension was 98.13 mmHg, in preeclampsia was 98.38 
mmHg and in Eclampsia was 107.75 mmHg as shown in figure-2.   
                        Mean MAP in normal mothers was 93.33 mmHg, in 
mothers with gestational hypertension was 111.88 mmHg, in preeclampsia 
was  118.72 mmHg and  in  Eclampsia was 128.25 mmHg as   shown    in 
figure-3.  The mean  SBP, DBP& MAP were significantly higher in cases 
than in controls.
                        Mean plasma homocysteine in normal mothers was 
10.50µmol/L, in mothers with gestational hypertension was 16.43µmol/L, in 
preeclampsia was 20.23µmol/L and in Eclampsia was 20.10µmol/L as 
shown in figure-5. Mean Plasma homocysteine levels were found to be 
significantly higher in cases    compared to controls. 
                       In our study there was no significant association  between  
age   and gestational hypertension  (p=0.523,table-2) and also no 
association  between parity  and   gestational  hypertension(p=0.230 ,table-
3). There were significant associations between live births and gestational 
hypertension (p<0.05). The higher the numbers of live children lower the 
occurrences of   gestational hypertension as depicted in table-4. There was 
no significant association (p=0.377) between no. of abortions and gestational 
hypertension as shown in table-5. 
                         There was no significant association between maternal blood 
group, child’s sex and gestational hypertension (p values 0.496, 0.343 
respectively) as seen in tables-6, 8. There was significant association 
between family history of cardiovascular disease and gestational 
hypertension (p<0.001) as in table-7. It was found that there was no 
significant association between the child’s birth weight and gestational 
hypertension (p=0.077) as shown in table-9. There was a significant 
association between plasma homocysteine levels and gestational 
hypertension (p<0.001).
                             Positive correlation was found between plasma 
homocysteine levels and MAP(r=0.447, p=0.000), SBP(r=0.559, p=0.000), 
DBP(r=0.334, p=0.000). There was also positive relationship between 
family history and MAP, SBP, DBP(r=0.360, p=0.000, r=0.438, p=0.000, 
r=0.276, p=0.003 respectively) as depicted in table-11.
                              It was found in the study that there was no significant 
association   between  plasma homocysteine   levels   and   age    (p=0.851), 
parity  (p=0.496) , no of live births (p=0.132), no of abortions   (p=0.221), 
child’s sex(p=0.721) and blood group(p=0.147) as seen in tables-
12,13,14,15,16&18. There was significant association between plasma 
homocysteine and positive family history of cardiovascular disease (p<0.05) 
as shown in table-17.
                        It was found that there was significant association between 
plasma homocysteine and   birth weight of babies (p<0.01) as depicted in 
table-19. There was significant association between diagnosis and plasma 
homocysteine levels (p<0.001) as shown in table-10.  It implies that 
homocysteine levels    in preeclampsia are higher than that in gestational 
hypertension.  
                       Ingec et al in 2005 showed that homocysteine concentration in 
severe preeclamptic and eclamptic women were significantly higher than 
mild preeclamptic and normotensive women concluding that elevated 
plasma homocysteine levels in early pregnancy can increase the risk of 
developing severe preeclampsia. These results are similar to our study.
                      Lopez et al in 2003 has results aligning with our study. It was
concluded that plasma homocysteine levels in gestation hypertension and 
preeclampsia were higher than that in normotensive controls. 
                          
                      El abd  et al  in 2009 conducted  a case control  study  similar 
to our study  which stated  that there was  a positive  correlation between 
plasma homocysteine levels and  SBP, DBP and MAP. It was also found 
that no significant correlation existed between plasma homocysteine levels 
and women’s age. It was found that MAP, SBP, DBP were higher in cases 
than in controls similar to our study.
                        Raijmaker et al in 2001 concluded in their study that plasma 
homocysteine levels were higher in preeclampsia and gestational 
hypertension compared to normotensives. This study is also similar to our 
study. 
                     Amir et al in 2006 also conducted a case control study along 
the lines of   our study and established that fasting plasma   homocysteine 
levels were higher in cases than in controls. 
                      Vincent et al in 2009 showed that mean homocysteine levels 
were higher in cases and a significant association existed between plasma 
homocysteine levels and gestational hypertension. It was also found that 
higher the homocysteine levels, higher are the SBP and DBP similar to our 
study.
                     
                         In our study it has been established that a relationship exists 
between plasma homocysteine levels and gestational hypertension. Also  it 
has  been  established  that plasma homocysteine  is  higher  if there  is 
positive  family  history of  cardiovascular disease. It was also found that 
plasma homocysteine levels are higher in preeclampsia than in gestational 
hypertension.
                      
                                        
Summary
SUMMARY
                   A case control study comprising 111 participants with 50 cases 
and 61 controls was done. Cases were postnatal mothers with gestational 
hypertension with BP more than 140/90 mmHg. Controls were normotensive 
women comparable in all aspects. A fasting sample of plasma homocysteine 
was obtained from all the cases and controls. Plasma homocysteine was 
measured using the Chemi luminescence immunoassay method.
                    The data obtained was subjected to statistical analysis. It was 
found   that the mean plasma homocysteine levels were higher in cases than 
in controls. It was also found that the plasma homocysteine levels were 
higher in preeclampsia than in gestational hypertension.  If there was 
positive  family history  of  cardiovascular  disease  then  plasma  
homocysteine  levels  were  found to be higher. Higher the SBP, DBP & 
MAP values, higher were the levels of plasma homocysteine. There was also 
evidence to state that there was association between elevated plasma 
homocysteine levels and birth weight of child. 
                    Thus the  study establishes  the  positive relationship  between  
plasma  homocysteine  levels   and  gestational  hypertension. 
                       These results are in conjecture with several studies done 
already. The  future  implications of this study is  that  based on  increased  
plasma  homocysteine  in women  with  gestational  hypertension 
Homocysteine  could  a potential  marker  for  predicting  gestational 
hypertension. 
Conclusion
CONCLUSION
                  It is concluded from this study that a relationship exists between 
plasma homocysteine levels and gestational hypertension. It is also 
concluded  that  higher  levels of  plasma  homocysteine levels  are found  in  
women  with gestational  hypertension  compared  to normotensive  
pregnant  women.  
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Annexure 
Proforma 
TAMILNADU Dr M.G.R. MEDICAL UNIVERSITY
       DEPT. OF OBSTETRICS AND GYNAECOLOGY
COIMBATORE MEDICAL COLLEGE
COIMBATORE
   PROFORMA
Name : 
Age & Sex : 
IP. No. /Unit: 
Parity:
Diagnosis:
Consent:
Case/Control:
Blood group:
Medical history:
Obstetric history: 
Family history:
Admission BP:
Mode of Delivery:
Child-Sex/Weight:
Plasma homocysteine levels:
Master Chart
MASTER  CHART
S.No Name Age IPNo Parity Live Abortion
Blood 
Group
Family 
H/O CVD
Diagnosis SBP DBP MAP
Mode of 
Delivery
Sex 
of 
the 
child
Birth 
wt  
of 
Child
P.Homocysteine
1 Vanithamani             21 47899 1 1 0 B+ve                    Positive E             170 110 130 LN 2 2.6 22.5
2 Sivaranjini             20 47672 1 1 0 O+ve                    Negative E        172 110 130.67 LN 2 3.1 32.4
3 Gowri                   24 41732 1 1 0 B+ve                    Negative PE 140 90 106.67 LSCS             2 3 11.28
4 Murugathal              21 46863 1 0 0 B+ve                    Positive E 180 90 120 LN                      2 2.6 23.09
5 Arulmani                25 47888 1 1 0 A+ve                    Positive GHT                140 90 106.67 LSCS             1 2.4 7
6 Babu                    33 48110 1 1 0 O+ve                    Positive GHT                140 90 106.67 LSCS             1 3.2 6
7 Kalamani                24 49202 2 1 0 O+ve                    Positive PE 160 90 113.33 LN                  2 3 44.31
8 Masilamani              32 46370 3 3 0 A+ve                    Positive PE 140 90 106.67 LSCS             2 3 15.61
9 Neelavathy              28 48218 2 2 2 B+ve                    Negative PE 140 90 106.67 LSCS             2 2.8 24.62
10 Kumudha                 22 47112 1 1 0 B+ve                    Negative PE 140 90 106.67 LSCS             1 2.7 19.34
11 Pandiselvi              27 49171 1 1 1 B+ve                    Negative PE 162 100 120.67 LSCS             2 2.6 15.56
12 Kalavathy               32 48142 2 2 0 B+ve                    Negative GHT                140 90 106.67 LSCS             1 2.4 11.36
13 Selvi                   21 49642 1 1 1 A+ve                    Negative N                    110 80 90 LN             2 3.2 13.04
14 Punitha                 23 49514 1 1 0 B+ve                    Negative N                    120 70 86.67 LN             1 3 15.15
15 Jameela                 18 49607 1 1 0 A+ve                    Negative N                    110 80 90 LN             2 3 11.45
16 Vennila                 23 48976 3 3 0 O+ve                    Negative N                    120 80 93.33 LN              1 2.8 16.92
17 Benazir banu            22 49720 2 1 1 A+ve                    Negative N                    110 80 90 LN                      2 2.7 9.97
18 Sneha                   19 49990 1 1 1 B+ve                    Positive PE 160 100 120 LSCS             1 2.6 39.93
19 Pushpa                  30 49822 3 3 0 A+ve                    Positive PE 140 90 106.67 LN                      2 2.4 25.06
20 Baby                    24 49862 1 1 0 A+ve                    Positive PE 160 110 126.67 LSCS             1 3.7 14.94
21 Lakshmi                 27 50100 1 1 0 O+ve                    Negative PE 142 90 107.33 LSCS             2 3.1 14.26
22 Shanthi poorani         28 48058 2 1 1 B+ve                    Negative PE 160 100 120 LN                  1 2.8 29.31
23 Rasmi                   20 50012 1 1 0 O+ve                    Negative N 110 80 90 LN                  1 3.7 16.08
24 Panchavarnam            25 49143 2 2 0 A+ve                    Negative E 170 110 130 LN                  2 3 17.36
25 Vijayalakshmi           18 50303 1 1 0 B+ve                    Negative E 162 110 127.33 LN                  1 3 24.95
26 Vijaya                  23 50375 2 2 0 O+ve                    Negative PE 150 108 122 LSCS             1 2.8 16.89
27 Kalpana                 21 50845 2 2 1 A-ve                    Negative N 110 70 83.33 LN             1 2.8 20.74
28 Geetha                  23 49752 1 1 0 AB+ve                   Negative GHT                140 100 113.33 LSCS             1 2.6 13.65
29 Thilagavathy            22 49739 1 1 0 O+ve                    Negative GHT                140 100 113.33 LSCS             2 2.5 16.7
30 Krishnaveni             27 50605 2 3 0 B+ve                    Negative GHT                140 90 106.67 LN 2 3 27.85
31 Ranganayaki             24 50673 1 1 0 O+ve                    Negative PE 160 110 126.67 LSCS             1 2.8 19.07
32 Vijayalakshmi           24 51077 1 1 1 B+ve                    Negative PE 140 100 113.33 LSCS             1 2.8 12.1
33 Sarawathy               20 50709 1 1 0 O+ve                    Positive PE 150 90 110 LSCS             1 2.6 19.65
34 Amutha                  24 50962 3 1 0 AB+ve                   Positive PE 160 90 113.33 LSCS             1 3 13.88
35 Jayanthi                26 51007 2 2 0 B+ve                    Negative GHT                140 100 113.33 LN                      1 2.8 10.4
36 Rekha                   22 51296 1 1 0 B+ve                    Negative GHT                140 90 106.67 LN                      2 3 20.47
37 Kaliammal               21 51210 1 0 0 O+ve                    Negative GHT                140 90 106.67 LN                      1 2.8 25.84
38 Sumathy                 24 50533 3 3 0 A+ve                    Negative PE 160 110 126.67 LN                      1 3 12.95
39 Thilaga                 22 50546 1 3 0 B+ve                    Negative GHT                140 100 113.33 LN                      1 2.8 28.82
40 Palaniyammal            27 51772 2 2 0 B+ve                    Negative PE 160 110 126.67 LN                      1 2.4 53.83
41 Ruckmani                38 52888 4 4 0 A+ve                    Positive PE 150 90 176.67 LSCS      1 3 12.79
42 Benazer                  18 52821 1 2 0 O+ve                    Positive PE 160 100 120 LN            2 3 19.88
43 Sakira Banu             22 52938 1 1 0 A+ve                    Positive E 180 110 133.33 LN            2 2.8 16.11
44 Sahana                  18 53499 1 1 0 A+ve                    Negative PE 150 100 116.67 LSCS           1 3 20.01
45 Selvi                   22 4467 2 2 0 B+ve                    Negative GHT 130 80 96.67 LN 1 2.6 9.12
46 Jothimani               21 9367 1 0 1 A+ve               Negative GHT 140 100 113.33 LN                      1 2.4 12.4
47 Rohini                  21 9924 1 0 0 O+ve                    Positive GHT 140 100 113.33 LN                      2 2.5 9.53
48 Kumudha                 30 10772 2 2 0 O+ve      Negative GHT 140 140 140 LN                      2 2.8 16.08
49 Devaki                  25 10128 1 0 0 O+ve                    Positive PE 150 100 116.67 LN                      1 2.5 16.36
50 Gayathri                22 9272 1 1 0 A+ve                    Positive PE 150 100 116.67 LSCS             2 2.8 12.38
51 Mallika                 22 9949 1 1 0 A+ve                    Negative E 160 112 128 LN 1 2.8 11.64
52 Abirami                 20 10016 1 1 0 O+ve                    Negative PE 160 110 126.67 LSCS             1 2.6 19.11
53 Vasantha                20 9425 1 1 0 B+ve                    Negative PE 160 110 126.67 LSCS             1 2.9 6.89
54 Sumathi                 23 9777 1 1 0 A+ve                    Negative PE 140 90 106.67 LSCS             1 3.4 16.06
55 Vasantha                27 10161 1 0 1 B+ve                    Negative E 160 110 126.67 LN                      1 2.8 12.73
56 Jhansi                  20 57136 1 1 0 O+ve                    Negative GHT 140 100 113.33 LN             1 3.1 29.84
57 Velumani                 24 5399 1 1 0 B+ve                    Negative GHT 140 110 120 LN             2 2.9 17.75
58 Parveen banu            27 58377 1 1 0 A+ve                    Negative N 120 80 93.33 LN             1 3.7 14.78
59 Sivaranjani             21 66124 1 1 0 B+ve                    Negative N 120 80 93.33 LSCS      2 2.9 8.16
60 Suganya                 22 66144 1 1 0 B+ve                    Negative N 120 80 93.33 LSCS     1 2.4 9.24
61 Saranya                 19 66145 1 1 0 A+ve                    Negative N 120 80 93.33 LN 1 2.7 8
62 Naseema Begam           24 66167 1 1 0 O+ve                    Negative N 120 80 93.33 LN 2 2.7 6.22
63 Meharunnisha            20 65771 1 1 0 A+ve                    Negative N 120 80 93.33 LN 2 2.4 7
64 Seerangi                32 66176 1 1 0 A+ve                    Negative N 120 80 93.33 LSCS      2 2.9 10.2
65 Renuka                  27 66186 2 2 0 B+ve                    Negative N 120 80 93.33 LN 2 2.8 11.44
66 Anupama                 22 66205 2 2 0 B+ve                    Negative N 130 90 103.33 LN 2 2.8 12.34
67 Kavitha                 20 66185 1 1 0 A+ve                    Negative N 120 80 93.33 LN 2 2.6 10.12
68 Shanthi                 23 66236 2 2 0 O+ve                    Negative N 120 80 93.33 LN 1 3.25 11
69 Renuka                  24 66217 2 2 0 A+ve                    Positive N 120 80 93.33 LSCS      2 3.2 9
70 Sarada                  22 65892 1 1 0 A+ve                    Negative N 120 80 93.33 LSCS             1 2.9 7.88
71 Kanageswari             23 66235 1 1 0 B+ve                    Negative N 120 80 93.33 LSCS             1 3.2 8.78
72 Rani                    20 66283 2 2 0 A+ve                    Negative N 120 80 93.33 LSCS             1 3.25 8
73 Deepa                   23 66272 2 2 0 O+ve                    Negative N 120 80 93.33 LN                      1 2.4 6.22
74 Arulmozhi               27 66292 1 1 0 O+ve      Negative N 120 80 93.33 LN             1 3 7
75 Prema                   23 66231 1 1 0 O+ve                    Negative N 130 90 103.33 LN             1 3 10.2
76 Vijayalakshmi           25 66296 1 1 0 A+ve                    Negative N 120 80 93.33 LN             2 2.5 11.12
77 Maheswari               25 66024 2 2 0 A+ve                    Negative N 120 80 93.33 LSCS      1 3.24 9.32
78 Kamatchi                25 66250 3 3 0 O+ve                    Negative N 120 80 93.33 LSCS      2 2.5 7.9
79 Kala                    29 64817 2 2 0 B+ve                    Negative N 120 80 93.33 LN 2 1.4 8.56
80 Sasikala                26 64207 2 2 0 A+ve                    Negative N 120 80 93.33 LN 1 2.5 10.74
81 Radhika                 20 66307 1 1 0 B+ve                    Negative N 120 80 93.33 LN 2 2.7 11.02
82 Shakunthalamani         26 66315 1 1 0 O+ve                    Negative N 120 80 93.33 LSCS      2 3.5 10.12
83 Latha                   24 66149 2 2 0 O+ve      Negative N 120 80 93.33 LN 1 2.5 15
84 Devika                  30 66422 2 2 0 A+ve                    Positive N 120 80 93.33 LN 1 2.4 9.8
85 Vennila                 21 66423 1 1 0 A+ve                    Negative N 120 80 93.33 LN 1 2.5 7.88
86 Sindhu                  22 66450 2 2 0 B+ve                    Negative N 120 80 93.33 LN 1 2.7 8.78
87 Usha                    21 66448 1 1 0 B+ve                    Negative N 120 80 93.33 LSCS      2 2.3 8
88 Santhi                  23 66402 3 3 0 A+ve                    Negative N 120 80 93.33 LSCS      1 2.75 6.22
89 Nandhini                20 66074 1 1 0 O+ve                    Negative N 120 80 93.33 LN 1 2.4 8.16
90 Rajathi                 20 66214 1 1 0 A+ve              Negative N 120 80 93.33 LN 2 2.5 9.24
91 Poongodi                23 66538 2 2 0 A+ve                    Negative N 120 80 93.33 LN 2 2.5 13.8
92 Jayasudha               28 66063 2 2 0 B+ve                    Negative N 120 90 100 LN 1 3.6 6.26
93 Mariammal               24 65150 2 2 0 A+ve                    Negative N 120 80 93.33 LSCS      1 2.5 14.12
94 Sathyakala              24 64182 2 2 0 O+ve                    Negative N 120 80 93.33 LSCS      1 2.7 10.2
95 Sudha                   24 66536 2 2 0 O+ve                    Negative N 120 80 93.33 LN 1 2.5 9.32
96 Anitha                  21 66542 1 1 0 O+ve                    Negative N 120 80 93.33 LN 2 3.1 7.9
97 Busra                   28 66647 4 4 0 A+ve                   Negative N 120 80 93.33 LSCS             2 3.1 8.56
98 Sakeelabanu             20 65742 1 1 0 A+ve                    Negative N 120 80 93.33 LSCS             1 2.9 12.32
99 Nimmy                   29 66693 2 2 0 O+ve                    Negative N 120 80 93.33 LSCS             1 2.75 13.62
100 Rajeswari               22 66707 1 1 0 B+ve                    Negative N 120 80 93.33 LN                      1 2.75 10.2
101 Jhansi                  20 66736 1 1 0 A+ve                    Negative N 120 80 93.33 LN             2 2.5 11.12
102 Sapna                   21 66684 2 2 0 B+ve                    Positive N 130 80 96.67 LN             2 2.7 9.32
103 Jayanthi                20 66577 1 1 0 O+ve                    Negative N 120 80 93.33 LN             2 2 7.9
104 Saini                   23 66702 1 1 0 B+ve                    Negative N 120 80 93.33 LSCS      2 2.9 8.56
105 Gayathri                21 66743 2 2 0 A+ve                    Negative N 120 80 93.33 LSCS      1 3 10.74
106 Soniadevi               22 66783 1 1 0 O+ve                    Negative N 120 80 93.33 LN 1 2.75 11.02
107 Pushpanjali             24 66599 2 2 0 A+ve                    Negative N 120 80 93.33 LN 1 3.25 10.12
108 Dhanalakshmi            23 66576 1 1 0 O+ve                    Negative N 120 80 93.33 LN 2 3.5 14.24
109 Santhi                  27 66846 2 2 0 B+ve                    Negative N 120 80 93.33 LSCS      2 3 12
110 Selvi                   20 66727 2 2 0 O+ve                  Negative N 120 80 93.33 LN 1 2.5 13.55
111 Gandhimathi             28 66543 1 1 0 B+ve                    Negative N 120 80 93.33 LN 2 2.7 14.68
Note:Age in years, N- Normal,GHT-Gestational hypertension,PE-Preeclampsia,E-Eclampsia,Family H/O CVD-Family History Of Cardiovascular Disease,In Sex of child 1- Male 
& 2- Female,P.Homocysteine in µmol\L, LN-Labour Naturale,LSCS-Lower segment caesarean section , Weight (Wt) in Kg  & SBP,DBP,MAP in mmHg.
Abbreviations 
ABBREVIATIONS
1 BP Blood pressure
2 PIH Pregnancy induced  hypertension
3 ALT Alanine aminotransferase
4 AST Aspartate aminotransferase
5 LDH Lactate dehydrogenase
6 WKS Weeks
7 PGI2 Prostacyclin I2 
8 TXA2 Thromboxane A2
9 NO Nitric  oxide 
10 NK cells Natural killer cells 
11 GFR Glomerular filtration rate
12 VEGF Vascular endothelial growth factor 
13 PLGF platelet growth factor
14 CTB Cytotrophoblast
15 STB Syncytiotrophoblast
16 Flt-1 Fms like tyrosine  kinase-1
17 KDR Kinase insert domain containing  
receptor 
18 S.Flt-1 Soluble Fms like tyrosine  kinase-1
19 S.ENG Soluble  endoglin
20 HLA Human  leukocyte  antigen
21 KIR Killer cell immunoglobulin like 
receptors 
22 TGF-b Transforming growth  factor –b
23 TNF Tumor necrosis factor 
24 IFN Interferon
25 THF Tetrahydrofolate
26 SAM S  adenosyl  methionine 
27 MTHFR Methylene tetrahydrofolate reductase
28 CBS Cystathionine beta  synthase
29 MS Methionine  synthase
30 HRT Hormone  replacement  therapy
31 OCP Oral  contraceptive pills
32 LDL low density lipoprotein
33 LP(a) Lipoprotein(a) 
34 Apo Apo lipoprotein
35 DVT Deep vein thrombosis
36 IUGR Intrauterine growth restriction.
37 EDTA Ethylene diamine  tetra  acetic acid 
38 MAP Mean  arterial  pressure
39 SBP Systolic Blood Pressure
40 DBP Diastolic  Blood Pressure
